US Edition
New WHO Guidelines Recommend Injectable Lenacapavir for HIV Prevention
KIGALI, RWANDA, JUL 14 – WHO urges immediate global use of twice-yearly injectable lenacapavir to address 1.3 million new HIV infections in 2024 and improve prevention among high-risk groups.
- On July 14, 2025, at the IAS 2025 conference in Kigali, WHO issued new guidelines recommending injectable lenacapavir twice yearly for HIV prevention.
- This guidance responds to 1.3 million new HIV infections reported in 2024 amid declining global funding threatening HIV prevention and treatment efforts.
- Lenacapavir, a long-acting antiretroviral, has demonstrated in clinical trials the ability to nearly eliminate new HIV infections, providing an important alternative to daily pill regimens that are often hindered by stigma and limited access.
- WHO Director-General Tedros Ghebreyesus called LEN "the next best thing," urging immediate rollout alongside simpler rapid HIV testing to increase accessibility.
- These guidelines could reshape the global HIV response, though experts stress bold, equitable implementation amid ongoing financial and systemic challenges worldwide.
37 Articles
37 Articles
WHO approves biannual HIV injection for global use
WHO emphasised the urgent need to make LEN widely accessible, through pharmacies, clinics, and online consultations, especially as global HIV prevention efforts are faltering The post WHO approves biannual HIV injection for global use appeared first on Premium Times Nigeria.
Africa: Momentum Builds For Long-Acting HIV Solutions As IAS 2025 Spotlights Scientific Progress, Funding Challenges And Leaders' Calls To Action
New WHO guidelines endorse long-acting injectable lenacapavir for HIV prevention, Medicines Patent Pool expands licence for long-acting injectable cabotegravir for treatment, and Merck's once-monthly oral pill MK-8527 advances to Phase 3 trials in Africa
WHO supports immediate rollout of new HIV jab
The World Health Organization (WHO) has officially recommended the global rollout of injectable lenacapavir (LEN), a long-acting HIV prevention jab that only needs to be taken twice a year. The announcement was made on Monday, July 14, 2025, during the 13th International AIDS Society Conference (IAS 2025) in Kigali, Rwanda. “While an HIV vaccine remains elusive, lenacapavir is the next best… Source
New WHO guidelines recommend injectable lenacapavir for HIV prevention
The World Health Organization (WHO) released today new guidelines recommending the use of injectable lenacapavir (LEN) twice a year as an additional pre-exposure prophylaxis (PrEP) option for HIV prevention, in a landmark policy action that could help reshape the global HIV response.
Expensive HIV drugs could be addressed via Asean regional cooperation
KUCHING, July 17 — Asean needs to establish a regional mechanism to tackle the high cost of antiretroviral (ARV) drugs for HIV treatment, said Deputy Health Minister Datuk Lukanisman Awang Sauni. He said the medications are critical in ensuring the continued success of HIV treatment programmes. “We must collectively explore strategies to secure better pricing, voluntary licensing, and regional procurement solutions. We must move forward not in i…
Coverage Details
Bias Distribution
- 60% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
